Rivipansel - GlycoMimetics/Pfizer

Drug Profile

Rivipansel - GlycoMimetics/Pfizer

Alternative Names: GM-1070; GMI-1070; PF-06460031; PF-6460031

Latest Information Update: 16 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlycoMimetics
  • Developer GlycoMimetics; Pfizer
  • Class Anti-inflammatories; Antianaemics; Antineoplastics; Glycolipids; Naphthalenesulfonates; Pyrimidines; Small molecules
  • Mechanism of Action E-selectin inhibitors; L-selectin inhibitors; P selectin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Sickle cell anaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Sickle cell anaemia
  • No development reported Haematological malignancies

Most Recent Events

  • 21 Feb 2018 Pfizer completes a phase I pharmacokinetics trial in USA (IV) (NCT02813798)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Haematological-malignancies(Combination therapy) in USA (IV, Infusion)
  • 23 Mar 2017 Pfizer completes a phase I pharmacokinetics trial in Healthy volunteers and subjects with hepatic impairment in USA (NCT02871570)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top